{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:44:10Z","timestamp":1790959450363,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The dementia epidemic, attributed to aging populations, represents a growing socio-economic burden. It is estimated that in 2019 about 55 million people worldwide were living with dementia. With many possible causes of dementia and the possibility of mixed dementia combining Alzheimer\u2019s disease (AD) and vascular dementia the question is whether diagnostic uncertainty exists or whether diagnostic constructs based on single etiologies are incorrect. Vascular Cognitive Impairment and Dementia (VCID) designates the extent of cognitive dysfunctions from the most benign state to that of dementia, of vascular origin. We reviewed epidemiological, pathophysiological and clinical data on VCID with a focus on VaD, as well as key data on the development of a new therapeutic solution, SaiLuoTong (MLC-SLT). From documentary research executed on different web sources (PubMed, <jats:ext-link>Clintrials.gov<\/jats:ext-link>, Z-library and Google), our initial selection for the short review of VCID and VaD was based on keywords contained in each paragraph subtitles of this article with exclusion of publications in a language other than English or published before 2010. For the review of SaiLuoTong development, there was just the language exclusion criterion. Sorted by relevance and publication date, 47 references were selected from 140 shortlisted for review. With new evidence-based classification systems, vascular cognitive impairment was proposed as umbrella term covering all forms of cognitive deficits related to vascular causes. The scope of application expanded with the VCID which includes VaD and mixed pathologies. No drugs are approved for the treatment of VaD by major Western regulatory agencies, while some traditional Chinese medicines are registered in China. VCID treatment should have a dual focus: managing the underlying cerebrovascular disease and dementia symptoms. This is the objective set for the development of the MLC-SLT, the essential data of which are reviewed in detail. To strengthen VCID and VaD research, consensus groups should attempt to consolidate scattered local research initiatives into coordinated international programs. In two VaD clinical trials, MLC-SLT improved cognitive symptoms and activities of daily living, with good safety and potential disease-modifying effect. In a placebo-controlled study in 325 patients with mild to moderate VaD and randomized according to a delayed-start design, MLC-SLT demonstrated significant improvement in memory tests and performance in executive function tasks, expanding its place in the management of VCID. At week 26, changes in VADAS-cog scores (SD) from baseline were 23.25 (0.45) for MLC-SLT 180\u00a0mg bid), 23.05 (0.45) for MLC-SLT 120\u00a0mg bid (both <jats:italic>p<\/jats:italic> &amp;lt; 0.0001), and 20.57 (0.45) for placebo (<jats:italic>p<\/jats:italic> = 0.15). At week 52, differences between both groups MLC-SLT and placebo were 2.67 and 2.48, respectively (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001), without significant difference between MLC-SLT groups.<\/jats:p>","DOI":"10.3389\/fphar.2024.1343820","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T04:50:42Z","timestamp":1714539042000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A review of SaiLuoTong (MLC-SLT) development in vascular cognitive impairment and dementia"],"prefix":"10.3389","volume":"15","author":[{"given":"Encarnita Raya","family":"Ampil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus Anam","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakup","family":"Krespi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"B1","volume-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"B2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12906-020-03102-3","article-title":"Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials","volume":"20","author":"Ayati","year":"2020","journal-title":"BMC Complement. Med. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jalz.2017.07.755","article-title":"Concomitant vascular and neurodegenerative pathologies double the risk of dementia","volume":"14","author":"Azarpazhooh","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD013306","DOI":"10.1002\/14651858.CD013306.pub2","article-title":"Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis","volume":"2","author":"Battle","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.3390\/molecules28103993","article-title":"The potential of Ginkgo biloba as a source of biologically active compounds-A review of the recent literature and patents","volume":"28","author":"Biernacka","year":"2023","journal-title":"Molecules"},{"key":"B6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.5603\/PJNNS.a2021.0035","article-title":"The assessment of cognitive and behavioural disturbances in vascular cognitive impairment (VCI) - recommendations of an expert working group","volume":"55","author":"Calabrese","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e071506","DOI":"10.1002\/alz.071506","article-title":"Efficacy of Sailuotong in Vascular Dementia: an exploratory analysis of possible disease modifying activity","volume":"19","author":"Chen","year":"2023","journal-title":"Alzheimer's Dement."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1147860","DOI":"10.3389\/fphar.2023.1147860","article-title":"Ginkgo biloba extract EGb 761\u00ae improves cognition and overall condition after ischemic stroke: results from a pilot randomized trial","volume":"14","author":"Cui","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e12385","DOI":"10.1002\/trc2.12385","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s11357-022-00556-w","article-title":"Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis","volume":"44","author":"Custodero","year":"2022","journal-title":"Geroscience"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.2174\/1570159X19666210113144703","article-title":"Crocus sativus L. (Saffron) in Alzheimer's disease treatment: bioactive effects on cognitive impairment","volume":"19","author":"D'Onofrio","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/nu14030597","article-title":"Saffron (Crocus sativus L.): a source of nutrients for health and for the treatment of neuropsychiatric and age-related diseases","volume":"14","author":"El Midaoui","year":"2022","journal-title":"Nutrients"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2013","DOI":"10.1212\/WNL.0000000000200255","article-title":"Association of cardiovascular risk trajectory with cognitive decline and incident dementia","volume":"98","author":"Farnsworth von Cederwald","year":"2022","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3233\/JAD-191046","article-title":"Neuroimaging in vascular cognitive impairment and dementia: a systematic review","volume":"73","author":"Frantellizzi","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40261-022-01136-8","article-title":"Benefits of treatment with Ginkgo biloba extract EGb 761 alone or combined with acetylcholinesterase inhibitors in vascular dementia","volume":"42","author":"Garc\u00eda-Alberca","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","article-title":"Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association\/american stroke association","volume":"42","author":"Gorelick","year":"2011","journal-title":"Stroke"},{"key":"B17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement."},{"key":"B18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/jad-2005-8105","article-title":"Patterns of healthcare utilization and costs for vascular dementia in a community-dwelling population","volume":"8","author":"Hill","year":"2005","journal-title":"J. Alzheimers Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2147\/NDT.S401231","article-title":"Ginkgo biloba extract EGb 761 in the treatment of patients with mild neurocognitive impairment: a systematic review","volume":"19","author":"Hort","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.jacc.2019.04.034","article-title":"Vascular cognitive impairment and dementia: JACC scientific expert panel","volume":"73","author":"Iadecola","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3389\/fnagi.2017.00333","article-title":"Systemic and disease-specific risk factors in vascular dementia: diagnosis and prevention","volume":"9","author":"Jaul","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fnagi.2013.00017","article-title":"Pathology and pathogenesis of vascular cognitive impairment\u2014a critical update","volume":"5","author":"Jellinger","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.trci.2018.02.004","article-title":"Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: a randomized clinical trial","volume":"4","author":"Jia","year":"2018","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-016-1571-z","article-title":"Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease","volume":"131","author":"Kalaria","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3233\/JAD-220239","article-title":"Costs of dementia in low- and middle-income countries: a systematic review","volume":"91","author":"Kenne Malaha","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.14336\/AD.2020.0427","article-title":"Pharmacological treatment of vascular dementia: a molecular mechanism perspective","volume":"12","author":"Kuang","year":"2021","journal-title":"Aging Dis."},{"key":"B27","first-page":"62","article-title":"A phase I tolerance and safety study of Sailuotong capsule","volume":"1","author":"Li","year":"2012","journal-title":"Chin. J. New Drugs."},{"key":"B28","doi-asserted-by":"publisher","first-page":"11067","DOI":"10.3390\/ijms231911067","article-title":"Clinical trials of new drugs for vascular cognitive impairment and vascular dementia","volume":"23","author":"Linh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/agm2.12230","article-title":"A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia","volume":"5","author":"Liu","year":"2022","journal-title":"Aging Med. Milt."},{"key":"B30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(03)00305-3","article-title":"Vascular cognitive impairment","volume":"2","author":"O'Brien","year":"2003","journal-title":"Lancet Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/S0140-6736(15)00463-8","article-title":"Vascular dementia","volume":"386","author":"O'Brien","year":"2015","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nrneurol.2014.181","article-title":"Classifying neurocognitive disorders: the DSM-5 approach","volume":"10","author":"Sachdev","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ijms18010095","article-title":"Sailuotong prevents hydrogen peroxide (H2O2)-induced injury in EA.hy926 cells","volume":"18","author":"Seto","year":"2017","journal-title":"Cells. Int. J. Mol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12967-020-02232-z","article-title":"Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial","volume":"18","author":"Shi","year":"2020","journal-title":"J. Transl. Med."},{"key":"B35","first-page":"895","article-title":"Evaluation of suspected dementia","volume":"84","author":"Simmons","year":"2011","journal-title":"Am. Fam. Physician"},{"key":"B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12906-016-0989-0","article-title":"The effect of Sailuotong (SLT) on neurocognitive and cardiovascular function in healthy adults: a randomised, double-blind, placebo controlled crossover pilot trial","volume":"16","author":"Steiner","year":"2016","journal-title":"BMC Complement. Altern. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e12420","DOI":"10.1002\/trc2.12420","article-title":"A randomized, double-blind, placebo-controlled, parallel-group 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment","volume":"9","author":"Steiner-Lim","year":"2023","journal-title":"Alzheimer's Dementia Transl. Res. Clin. Interventions"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.2174\/1570159X15666171016164734","article-title":"Potential therapeutics for vascular cognitive impairment and dementia","volume":"16","author":"Sun","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jgr.2023.03.001","article-title":"Panax Ginseng in the treatment of Alzheimer's disease and vascular dementia","volume":"47","author":"Wang","year":"2023","journal-title":"J. Ginseng Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"CXI","DOI":"10.1177\/23969873211012132","article-title":"ESO Guideline on covert cerebral small vessel disease","volume":"6","author":"Wardlaw","year":"2021","journal-title":"Eur. Stroke J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/S1041610203009281","article-title":"Societal burden and economics of vascular dementia: preliminary results from a Swedish-population-based study","volume":"15","author":"Wimo","year":"2003","journal-title":"Int. Psychogeriatr."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/ATVBAHA.119.311908","article-title":"Epidemiology of vascular dementia","volume":"39","author":"Wolters","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B43","volume-title":"Global status report on the public health response to dementia","year":"2021"},{"key":"B44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.26599\/BSA.2018.9050001","article-title":"Vascular contribution to cognition in stroke and Alzheimer\u2019s disease","volume":"4","author":"Yang","year":"2018","journal-title":"Brain Sci. Adv."},{"key":"B45","doi-asserted-by":"publisher","first-page":"8125805","DOI":"10.1155\/2020\/8125805","article-title":"Endothelium-independent vasodilatory effect of sailuotong (SLT) on rat isolated tail artery","volume":"2020","author":"Yeon","year":"2020","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.3390\/jcm11164742","article-title":"A study on the pathogenesis of vascular cognitive impairment and dementia: the chronic cerebral hypoperfusion hypothesis","volume":"11","author":"Yu","year":"2022","journal-title":"J. Clin. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"8416105","DOI":"10.1155\/2019\/8416105","article-title":"Sailuotong capsule prevents the cerebral ischaemia-induced neuroinflammation and impairment of recognition memory through inhibition of LCN2 expression","author":"Zhang","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/alz.12157","article-title":"Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 national heart, lung, and blood Institute and national Institute of neurological disorders and stroke workshop","volume":"16","author":"Zlokovic","year":"2020","journal-title":"Alzheimers Dement."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1343820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T04:50:47Z","timestamp":1714539047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1343820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":48,"alternative-id":["10.3389\/fphar.2024.1343820"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1343820","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"article-number":"1343820"}}